Saidal Pursues African Vaccine Markets After Syntegon Talks

Algerian state-owned pharmaceutical group Saidal is targeting African vaccine markets and seeking access to UNICEF procurement programs, supported by national efforts to enhance domestic production capacity. This strategic move was recently highlighted by Pharmaceutical Industry Minister Wassim Kouidri's discussions with German engineering group Syntegon in Germany. The talks centered on finalizing technical and commercial arrangements for a specialized vaccine manufacturing line intended for Saidal, although no agreement was formally announced following the meeting.

The initiative is part of a broader drive to strengthen national control over the vaccine supply chain, reduce reliance on imports, and reinforce Algeria’s health sovereignty, aligning with President Abdelmadjid Tebboune's instructions for domestic production to cover the full range of official immunisation schedule vaccines. Syntegon specializes in pharmaceutical processing, including sterile packaging systems, and Minister Kouidri inspected advanced automated manufacturing modules during his visit, which could offer significant operational advantages by limiting human intervention in sensitive production environments.

Beyond vaccine self-sufficiency, Saidal is pursuing a wider industrial relaunch, including the construction of a raw-material plant for antibiotic production in Médéa and the restart of production lines at the former Hup Pharma facility in Constantine. The resumption of the solvent-distillation unit in Médéa also paves the way for penicillin G production. Algeria's strategy for regional expansion includes technology-transfer partnerships with international manufacturers, such as an agreement with Germany’s Boehringer Ingelheim, with further discussions underway with US partners on influenza vaccines and cell therapy, positioning Saidal as a potential regional pharmaceutical supplier.